Equities

Roivant Sciences Ltd

Roivant Sciences Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)12.04
  • Today's Change0.215 / 1.82%
  • Shares traded1.11m
  • 1 Year change+33.72%
  • Beta1.2324
Data delayed at least 15 minutes, as of Nov 22 2024 15:16 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy4
Outperform6
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The 8 analysts offering 12 month price targets for Roivant Sciences Ltd have a median target of 16.50, with a high estimate of 22.00 and a low estimate of 12.50. The median estimate represents a 39.59% increase from the last price of 11.82.
High86.1%22.00
Med39.6%16.50
Low5.8%12.50

Earnings history & estimates in USD

On Nov 12, 2024, Roivant Sciences Ltd reported 2nd quarter 2025 losses of -0.31 per share.
The next earnings announcement is expected on Feb 11, 2025.
Roivant Sciences Ltd reported annual 2024 earnings of 5.23 per share on May 30, 2024.
Average growth rate-25.40%
More ▼

Revenue history & estimates in USD

Roivant Sciences Ltd had 2nd quarter 2025 revenues of 29.26m. This missed the 49.22m consensus estimate of the 8 analysts following the company. This was 35.32% above the prior year's 2nd quarter results.
Average growth rate+5.41%
Roivant Sciences Ltd had revenues for the full year 2024 of 124.80m. This was 103.65% above the prior year's results.
Average growth rate+57.24%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.